CG Oncology, Inc. (CGON) AI Stock Analysis

• Market Cap: $1.99B
• Dividend Yield: N/A
• Average Volume (3M): 901.07K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.94
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 113
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -0.45
• Shares Outstanding: 76,225,310
• 10 Day Avg. Volume: 1,156,633
• 30 Day Avg. Volume: 901,070
• PEG Ratio: 2.87
• Price to Book (P/B): 2.70
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -23.19
• Enterprise Value/Market Cap: 0.94
• Enterprise Value/Revenue: 593.74
• Enterprise Value/Gross Profit: 2.84K
• Enterprise Value/Ebitda: -4.37
• 1Y Price Target: $54.13
• Price Target Upside: 107.39% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 49 Neutral
• Price Target: $26.00 ▼(-0.38%Downside)

CG Oncology, Inc. faces financial hurdles typical of early-stage biotech companies, with no current revenue and reliance on external funding. While technical indicators show neutral momentum, the valuation reflects challenges in achieving profitability. Promising trial results provide a potential future catalyst, but immediate financial and operational improvements are necessary to enhance the company's stock outlook.

Positive Factors

Launch and Uptake Potential

There is confidence in creto's launch and uptake potential, which should outperform the early trajectory observed with other therapies.

Market Opportunity

The analyst remains positive on the market opportunity and label expansion potential for creto.

Product Differentiation

Creto is meaningfully differentiated by its durability and safety data, which supports further upside for creto in additional indications and combinations with other therapies.

Negative Factors

Adverse Events Concerns

Durability for creto may be slightly more impressive but is awaiting further follow-up.

Competitor Comparison

Dr. Ghodoussipour was a bit hesitant on the higher frequency of grade 3+ TRAEs and discontinuations with TAR-200.

Data Risk

Creto's clinical positioning in BCG-unresponsive, high-risk NMIBC was strengthened by the disappointing TAR-200 data.

CG Oncology, Inc. Business Overview & Revenue Model

Company Description

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

How the Company Makes Money

CG Oncology, Inc. makes money primarily through the development and commercialization of its proprietary oncolytic immunotherapy treatments. The company's revenue model includes the potential for milestone payments, royalties, and licensing fees from partnerships with larger pharmaceutical companies. These partnerships may involve collaborative research and development agreements or licensing agreements for the distribution and marketing of CG Oncology's therapies. Additionally, the company may pursue direct commercialization of its products, subject to successful clinical trials and regulatory approval, to generate revenue through product sales.

CG Oncology, Inc. Financial Statement Overview

Summary

CG Oncology, Inc. is experiencing financial challenges typical of early-stage biotech firms, with no revenue and significant operating losses. However, the strong equity position and cash reserves provide some stability, despite the reliance on external funding for operations.

Income Statement

CG Oncology, Inc. reported zero revenue in the latest year, indicating challenges in generating income. The company has experienced consistent losses with deteriorating EBIT and EBITDA margins, reflecting operational inefficiencies and potential barriers in monetizing its biotechnology developments.

Balance Sheet

The company's strong equity base relative to total assets, demonstrated by a high equity ratio, provides a solid financial foundation. However, the minimal debt levels and high cash reserves suggest limited leverage but also an underutilization of potential financing for growth.

Cash Flow

The negative free cash flow and significant negative operating cash flow highlight ongoing cash burn issues. Despite substantial financing inflows, the company is heavily reliant on external funding for operations, which could pose risks if such funding diminishes.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.14M	204.00K	191.00K	10.36M
Gross Profit	1.14M	204.00K	176.00K	10.35M
EBITDA	-114.63M	-55.43M	-35.23M	-12.38M
Net Income	-88.04M	-48.61M	-35.44M	-12.84M
Balance Sheet
Total Assets	754.80M	199.30M	147.75M	58.69M
Cash, Cash Equivalents and Short-Term Investments	742.00M	187.67M	143.48M	53.61M
Total Debt	238.00K	461.00K	16.30M	15.48M
Total Liabilities	21.42M	14.51M	22.57M	18.44M
Stockholders Equity	733.38M	184.79M	125.18M	40.25M
Cash Flow
Free Cash Flow	-78.95M	-45.68M	-29.82M	-13.75M
Operating Cash Flow	-78.71M	-45.68M	-29.80M	-13.65M
Investing Cash Flow	-300.76M	-121.19M	-55.35M	-97.00K
Financing Cash Flow	628.28M	87.00M	119.69M	15.45M

CG Oncology, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 26.10
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CGON, the sentiment is Negative. The current price of 26.1 is below the 20-day moving average (MA) of 26.43, below the 50-day MA of 26.17, and below the 200-day MA of 28.51, indicating a bearish trend. The MACD of 0.08 indicates Positive momentum. The RSI at 48.77 is Neutral, neither overbought nor oversold. The STOCH value of 37.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CGON.

CG Oncology, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IDYA	56 Neutral	$2.15B	―	-31.34%	―	-54.85%	-79.25%
Sector *	56 Neutral	$6.23B	21.98	-28.61%	4.90%	10.73%	-32.66%
BEAM	56 Neutral	$2.18B	―	-38.04%	―	-82.38%	-164.76%
ARQT	54 Neutral	$1.77B	―	-70.58%	―	100.03%	64.22%
CGON	49 Neutral	$1.99B	―	-16.57%	―	―	―
IRON	43 Neutral	$2.10B	―	-23.34%	―	―	-14.19%
COGT	37 Underperform	$1.98B	―	-84.04%	―	―	-2.53%

CG Oncology, Inc. Corporate Events

CG Oncology Appoints Interim CFO After Resignation

CG Oncology, Inc. announced that its Chief Financial Officer, Corleen Roche, has resigned, with her departure effective on August 5, 2025. The company has appointed Robert Lapetina as the interim principal financial and accounting officer, effective the same date, until a permanent replacement is found.

The most recent analyst rating on (CGON) stock is a Buy with a $66.00 price target. To see the full list of analyst forecasts on CG Oncology, Inc. stock, see the CGON Stock Forecast page.

CG Oncology Holds 2025 Annual Stockholders Meeting

On June 5, 2025, CG Oncology, Inc. held its 2025 Annual Meeting of Stockholders where key decisions were made regarding the company’s leadership and auditing practices. The stockholders elected three Class I directors to serve until the 2028 Annual Meeting and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (CGON) stock is a Buy with a $86.00 price target. To see the full list of analyst forecasts on CG Oncology, Inc. stock, see the CGON Stock Forecast page.

CG Oncology Announces Promising Phase 3 Trial Results

On April 26, 2025, CG Oncology announced promising results from its Phase 3 BOND-003 clinical trial at the American Urological Association Annual Meeting. The trial data showed a 75.5% complete response rate at any time for patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer treated with cretostimogene grenadenorepvec. The 24-month complete response rate was 42.3%, with a median duration of response of 28 months. Additionally, 97.3% of patients remained free from progression to muscle-invasive disease, and the treatment was well-tolerated with no severe adverse events reported. Cohort P also showed a high-grade recurrence-free survival rate of 90.5% at 3 and 9 months. These results position cretostimogene as a potential breakthrough therapy for bladder cancer, offering distinct advantages over existing treatments.